Article ID Journal Published Year Pages File Type
5525470 Cancer Letters 2016 9 Pages PDF
Abstract

•Cancer is a heterogeneous and complex disease that presents several dynamic modifications in protein machinery.•Mass spectrometry represents one of the most powerful initial approach for screening the differentially expressed proteins in cancer.•Tumor heterogeneity represents the primary challenge to cancer proteomic studies.•The capability to analyze serum proteomics by examining low-abundance proteins allows identifying reliable markers.

Proteomics has emerged as a promising field in the post-genomic era. Notwithstanding the great advances provided by gene expression analysis in cancer, the lack of a correlation between gene expression and protein levels has highlighted the need for a proteomic focus on cancer. Although the increasing knowledge regarding cancer biology, a reliable marker to improve diagnosis, prognosis and treatment for cancer patients is not a reality at present. In this review, we address the main considerations regarding proteomics-based studies and their clinical applications on cancer research, highlighting some considerations related to strengths and limitations of proteomics-based studies and its application to clinical practice.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , ,